ChemoCentryx Inc. (NASDAQ:CCXI) shares saw an uptick in trading volume on Friday . 594,773 shares traded hands during trading, an increase of 199% from the previous session’s volume of 199,040 shares.The stock last traded at $4.51 and had previously closed at $5.29.

A number of research firms have recently issued reports on CCXI. Zacks Investment Research downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $11.00 price target on shares of ChemoCentryx in a research report on Tuesday, August 9th. Finally, Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th.

The stock has a 50-day moving average of $4.61 and a 200 day moving average of $3.89. The company’s market capitalization is $201.56 million.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.